One recent study has shown that a model using repeated NTG injections holds promise for studying the ontogeny of migraine as a chronic disorder [15].
A mixed-effects model using repeated measures of Alu or LINE-1 as the dependent variable and blood/bone lead (tibia or patella in separate models) as the primary exposure marker was fit to the data.
In the present study, we were able to validate the antinociceptive effects of HA preparations in a highly reproducible animal pain model using repeated intra-articular injections of bradykinin and PGE2.
The Model using mean exposure across visits as a summary and random intercepts from the Two stage mixed effects model use repeated measures that can more powerfully detect such an effect than any single measurement model, e.g. the Multiple logistic regression model and the Parallel cross-sectional logistic regression models, regardless of the number of exposure measurements available.
Data were analyzed in linear mixed models using repeated measures within herd where MFP was considered the outcome variable.
Results from logistic and negative binomial regression models, using repeated data measures, indicated that JBTC participants, relative to baseline and a sample of comparison youth, were significantly less likely to be arrested and had significantly fewer arrests in the six to twelve months after entering the program.
Mixed-effects models were used to assess effects of pollutants, SNPs, and interactions under recessive inheritance models using repeated measures.
In the second animal model we used repeated measurements (if available) from the same individual, henceforth called repeated measures animal model, and this included fixed effects (instead of corrected values).
In the second model, we used repeated measures of the same individual, thereby producing estimates that may not only be influenced by the use of a larger pedigree but also by information about variation within individuals.
In the general linear model, we used repeated measures to test the sequential changes in HbA1c from month 6 to month 48.
